Article
Chemistry, Multidisciplinary
Yimin Niu, Hongbin Yang, Zhenyan Yu, Cuicui Gao, Shuaishuai Ji, Jie Yan, Lei Han, Qiang Huo, Ming Xu, Yang Liu
Summary: Bone metastasis is a common phenomenon in lung cancer, prostate cancer, and other malignant tumors. In this study, biomineralized metal-organic framework (MOF) nanoparticles carrying protein toxins and combined with RANKL antibody were constructed to effectively treat bone metastases and reduce skeletal-related events (SREs).
Article
Oncology
Go Saito, Takahiro Ebata, Tsukasa Ishiwata, Shunichiro Iwasawa, Ichiro Yoshino, Yuichi Takiguchi, Koichiro Tatsumi
Summary: This study reviewed the medical records of 238 consecutive NSCLC patients treated with BMAs and identified risk factors such as performance status, gender, and type of bone-modifying agent that can affect the occurrence of SREs. Careful observation is needed for patients with these identified risk factors.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Oncology
Terry L. Ng, Megan M. Tu, Mohammed F. K. Ibrahim, Bassam Basulaiman, Sharon F. McGee, Amirrtha Srikanthan, Ricardo Fernandes, Lisa Vandermeer, Carol Stober, Marta Sienkiewicz, Ahwon Jeong, Deanna Saunders, Arif A. Awan, Brian Hutton, Mark J. Clemons
Summary: A systematic review was conducted on the risk-benefit of using bone-modifying agents (BMAs) for more than 2 years in breast cancer or castrate-resistant prostate cancer patients. The evidence suggests that BMAs may reduce skeletal-related event rates but have limited impact on quality of life, with potential risks of osteonecrosis of the jaw and other toxicities. Prospective randomized studies with a focus on quality of life are needed to better inform the use of BMAs beyond 2 years.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Oncology
Esmeralda Garcia-Torralba, Francesca Spada, Kok Haw Jonathan Lim, Timothy Jacobs, Jorge Barriuso, Was Mansoor, Mairead G. McNamara, Richard A. Hubner, Prakash Manoharan, Nicola Fazio, Juan W. Valle, Angela Lamarca
Summary: The systematic review and meta-analysis revealed that BM prevalence in NENs patients is 18.4%, with mainly osteoblastic and multifocal characteristics, pain being the most common symptom. Various treatment modalities are used with limited evidence available for their efficacy.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Mashari Alzahrani, Carol Stober, Michelle Liu, Arif Awan, Terry L. Ng, Gregory Pond, Bader Alshamsan, Lisa Vandermeer, Mark Clemons
Summary: This retrospective study evaluated the effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with metastatic breast and castration-resistant prostate cancer. The results showed that the first year after diagnosis of bone metastasis had the highest risk for SSEs.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Mathematical & Computational Biology
Gao Zhang, Hu Gong, Hanqiao Xu
Summary: Bisphosphonates have shown promising results in improving quality of life, emotional state, pain relief, serum calcium level, immune function, and reducing inflammatory response in patients with lung cancer and bone metastases.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
(2021)
Article
Pharmacology & Pharmacy
R. Berardi, A. Berruti, L. Brogelli, P. A. Zucali
Summary: The survey revealed that Italian oncologists tend to use bone-targeted therapy to prevent skeletal-related events in patients with metastatic breast, prostate, or lung cancer, in line with current recommendations.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
Pei-An Fu, Chin-Yao Shen, Shuen-Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung
Summary: Denosumab reduces skeletal-related events (SREs) in breast cancer patients with bone metastases, but its long-term efficacy and safety are limited by lack of real-world data. This retrospective study on 132 denosumab-treated patients found that 11.1% experienced SREs in the first year, with the rate increasing over time. Additionally, 7.6% developed osteonecrosis of the jaw (ONJ), but most of those who resumed denosumab did not experience recurrence of ONJ.
SCIENTIFIC REPORTS
(2023)
Review
Cell Biology
Camille Gaudet, Stephane Odet, Christophe Meyer, Brice Chatelain, Elise Weber, Anne-Laure Parmentier, Stephane Derruau, Sebastien Laurence, Cedric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Mathilde Fenelon, Jean-Christophe Fricain, Narcisse Zwetyenga, David Hoarau, Remi Curien, Eric Gerard, Aurelien Louvrier, Florelle Gindraux
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a complication caused by anti-resorptive agents and anti-angiogenesis drugs. We reviewed the literature and designed a questionnaire to collect information on clinical practices. However, we found missing data and a lack of consensus.
Article
Pharmacology & Pharmacy
Andrew H. Tam, Allison J. Schepers, Angel Qin, Victoria R. Nachar
Summary: This study is the first to examine the extended-interval dosing of zoledronic acid in metastatic lung cancer patients. The incidence and time to skeletal-related events at 1 year were similar between the Q12wk and Q4wk dosing groups, but the Q12wk dosing group had a longer overall survival time.
ANNALS OF PHARMACOTHERAPY
(2021)
Article
Oncology
Hirotaka Miyashita, Christina Cruz, Cardinale Smith
Summary: This study identified osteolytic bone metastasis, low serum albumin, and elevated serum alkaline phosphatase as risk factors for skeletal-related events in patients with bone metastasis from non-small cell lung cancer.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Georg Herget, Babak Saravi, Eugenia Schwarzkopf, Mara Wigand, Norbert Suedkamp, Hagen Schmal, Markus Uhl, Gernot Lang
Summary: Skeletal-related events due to bone metastases significantly impact cancer patient morbidity and mortality. This study investigated clinicopathological characteristics, metastasis-free survival, and SREs in patients referred to a tertiary orthopedic and trauma center. Breast and lung cancer were most common in women, while lung and prostate cancer were most common in men, with age and primary cancer grading showing prognostic relevance.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Maria Antonia Gomez-Aparicio, Fernando Lopez-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renee Bultijnck, Paul Sargos, Piet Ost, Felipe Counago
Summary: Maintaining optimal bone health is crucial for the management of prostate cancer, especially in older and frail patients and those who experience bone loss or bone metastases due to treatment. Bisphosphonates and denosumab have shown promising results in improving bone mineral density and reducing the risk of skeletal-related events in these patients.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Article
Oncology
Hirotaka Miyashita, Christina Cruz, Vaibhav Patel
Summary: This study analyzed clinical data from patients with bone metastatic prostate cancer and identified potential risk factors for skeletal-related events (SREs) such as history of SREs, Gleason score >= 7, elevated serum alkaline phosphatase, and high urine N-telopeptide cross-links/creatinine ratio.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Respiratory System
Brendan J. Knapp, Siddhartha Devarakonda, Ramaswamy Govindan
Summary: Bone metastases significantly impact the prognosis, function, and symptoms of lung cancer patients. Bisphosphonates and/or denosumab should be considered for all patients with bone metastases. Further studies comparing the genetic alterations of skeletal metastases and primary tumors are needed. The interaction between immunotherapy and bone metastases and the response to treatment in bone require more investigation.
JOURNAL OF THORACIC DISEASE
(2022)
Article
Oncology
Nika Guberina, Christoph Poettgen, Martin Schuler, Maja Guberina, Georgios Stamatis, Till Ploenes, Bettina Krebs, Martin Metzenmacher, Dirk Theegarten, Thomas Gauler, Karl-Heinz Joeckel, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Wilfried E. Eberhardt
EUROPEAN JOURNAL OF CANCER
(2020)
Article
Oncology
Martin Metzenmacher, Moritz Goetz, Thomas Herold, Martin Stuschke, Clemens Aigner, Kaid Darwiche, Wilfried E. Eberhardt, Martin Schuler, Marcel Wiesweg
Summary: Therapy with BRAF plus MEK-inhibitor is an approved principle for treating BRAF V600-mutated NSCLC. Understanding mechanisms of resistance against this therapy is crucial, particularly in the context of MAPK reactivation leading to increased ERK signaling. Rebiopsy for detecting BRAF V600 mutation is emphasized for monitoring disease progression.
CLINICAL LUNG CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maja Guberina, Kaid Darwiche, Hubertus Hautzel, Till Ploenes, Christoph Poettgen, Nika Guberina, Ken Herrmann, Lale Umutlu, Axel Wetter, Dirk Theegarten, Clemens Aigner, Wilfried Ernst Erich Eberhardt, Martin Schuler, Ruediger Karpf-Wissel, Martin Stuschke
Summary: Incorporating systematic mediastinal LN mapping through EBUS-TBNA in addition to PET/CT can improve the accuracy of target volume definition, especially in echelon-3 LNs. EBUS-TBNA is recommended as an integral part of staging for radiochemotherapy in stage III NSCLC.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, Marcel Reiser, Mark-Oliver Zahn, Christoph Maintz, Christiane Bernhardt, Christoph Losem, Albrecht Stenzinger, Lukas C. Heukamp, Reinhard Buettner, Norbert Marschner, Martina Jaenicke, Annette Fleitz, Lisa Spring, Joerg Sahlmann, Aysun Karatas, Annette Hipper, Wilko Weichert, Monika Heilmann, Parvis Sadjadian, Wolfgang Gleiber, Christian Grah, Cornelius F. Waller, Martin Reck, Achim Rittmeyer, Petros Christopoulos, Martin Sebastian, Michael Thomas
Summary: The testing rates for biomarkers in advanced NSCLC patients in Germany are high but still leave out a significant portion of patients who could potentially benefit, highlighting the need for specific measures to increase implementation.
Review
Oncology
Nadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried E. E. Eberhardt, Jens P. Klussmann, Barbara Wollenberg, Marc-Oliver Grimm, Thomas Zander, Diana Lueftner
Summary: HTA plays an essential role in evaluating the clinical and economic value of new interventions for cancer patients. While overall survival is a preferred criterion, incorporating end-points like pathological complete response and disease-free survival is crucial for patients with early cancer, as they provide important psychological benefits.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Lea M. Schotten, Kaid Darwiche, Michal Seweryn, Vedat Yildiz, Peter J. Kneuertz, Wilfried E. E. Eberhardt, Stephan Eisenmann, Stefan Welter, Brianna E. Sisson, Maciej Pietrzak, Marcel Wiesweg, Till Ploenes, Thomas Hager, Kai He, Lutz Freitag, Clemens Aigner, Christian Taube, Filiz Oezkan
Summary: This study aimed to evaluate the predictive ability of DNA hypermethylation of SHOX2 and PTGER4 in plasma to discriminate between lung cancer, benign lesions, and COPD patients. The results showed that PTGER4 DNA hypermethylation was significantly more frequent in lung cancer patients compared to controls, which may serve as a biomarker to support clinical decision-making. Further exploration in prospective studies is needed.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Marcel Wiesweg, Cedric Preuss, Julia Roeper, Martin Metzenmacher, Wilfried Eberhardt, Ursula Stropiep, Katrin Wedeken, Henning Reis, Thomas Herold, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Hans-Ulrich Schildhaus, Kurt W. Schmid, Markus Falk, Lukas Heukamp, Markus Tiemann, Frank Griesinger, Martin Schuler
Summary: BRAF mutations in NSCLC patients have different subtypes, with V600E being the most common, but a majority of patients harbor other BRAF mutations of functional classes II/III. Despite the poor prognosis of BRAF-mutated NSCLC, they exhibit high susceptibility to immune checkpoint inhibitors compared to other tractable driver mutations in NSCLC.
EUROPEAN JOURNAL OF CANCER
(2021)
Editorial Material
Oncology
Martin Sebastian, Jan Alexander Stratmann, Wilfried E. E. Eberhardt
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Martin Sebastian, Wilfried E. E. Eberhardt, Petra Hoffknecht, Martin Metzenmacher, Thomas Wehler, Konrad Kokowski, Juergen Alt, Wolfgang Schuette, Reinhard Buettner, Lukas C. Heukamp, Albrecht Stenzinger, Martina Jaenicke, Annette Fleitz, Stefan Zacharias, Stephanie Dille, Annette Hipper, Marlen Sandberg, Wilko Weichert, Matthias Groschek, Eyck von der Heyde, Jacqueline Rauh, Tobias Dechow, Michael Thomas, Frank Griesinger
Summary: The study analyzed treatment outcomes of 1039 patients with advanced KRAS-mutant or wildtype NSCLC in Germany and found higher proportion of patients with G12C and non-G12C mutations receiving first-line treatment combined with immune checkpoint inhibitors. It was also observed that high PD-L1 expression (TPS>50%) was associated with a significantly decreased risk of mortality.
Article
Oncology
Justin Ferdinandus, Martin Metzenmacher, Lukas Kessler, Lale Umutlu, Clemens Aigner, Kambartel Otto Karl, Viktor Gruenwald, Wilfried Eberhardt, Wolfgang Peter Fendler, Ken Herrmann, Martin Faehling, Daniel Christian Christoph
Summary: After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cardiac & Cardiovascular Systems
Georgios Stamatis, Stefanie Mueller, Gerhard Weinreich, Birte Schwarz, Wilfried Eberhardt, Christoph Pottgen, Clemens Aigner
Summary: This study aimed to identify subgroups with persistent N2 disease in NSCLC after neoadjuvant treatment, and determine if these subgroups could benefit from surgery. The results showed that lobectomy or bilobectomy could be a potentially curative option with promising long-term results for patients with persistent single-station N2 involvement, either skip or additionally with N1 status, after induction treatment.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Correction
Oncology
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, Marcel Reiser, Mark-Oliver Zahn, Christoph Maintz, Christiane Bernhardt, Christoph Losem, Albrecht Stenzinger, Lukas C. Heukamp, Reinhard Buettner, Norbert Marschner, Martina Jaenicke, Annette Fleitz, Lisa Spring, Joerg Sahlmann, Aysun Karatas, Annette Hipper, Wilko Weichert, Monika Heilmann, Parvis Sadjadian, Wolfgang Gleiber, Christian Grah, Cornelius F. Waller, Martin Reck, Achim Rittmeyer, Petros Christopoulos, Martin Sebastian, Michael Thomas
Article
Respiratory System
C. Aigner, T. Bruening, W. E. E. Eberhardt, M. Haerter, H-P Kaelberlah, M. Metzenmacher, R. Shah, C. Taube, M. Thomas
Summary: Asbestos-related mesotheliomas are among the most frequent occupational diseases in Germany, with a poor prognosis. Efforts to advance early diagnosis and individualized therapy have been made, with standard treatments including surgery, chemotherapy, and radiotherapy while new therapeutic avenues are being explored.
Article
Oncology
Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, Niels Reinmuth, Martin Sebastian, Monika Serke, Cornelius Florian Waller, Michael Thomas, Jochen Eggert, Gerald Schmid-Bindert, Mathias Hoiczyk, Daniel Christian Christoph, Martin Kimmich, Burkhard Deuss, Stephanie Seifert, Swantje Held, Martin Schuler, Thomas Herold, Frank Breitenbuecher, Wilfried Ernst Erich Eberhardt
Summary: The study compared the efficacy and safety of split-dose cisplatin with the standard schedule in non-squamous non-small-cell lung cancer treatment, finding no significant differences in objective response rate and overall survival, but a slightly better progression-free survival in the split-dose cisplatin group. The advantages of split-dose cisplatin in specific toxicities allow for personalized chemotherapy treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q. M. Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Aren Frontera, Rita Chiari, Charles Butts, Joanna Wojcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, Miriam Alonso Garcia, David Waterhouse, Manuel Domine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E. Gerber, Grzegorz Czyzewicz, David R. Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.
JOURNAL OF CLINICAL ONCOLOGY
(2021)